Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review

J Chemother. 2024 Nov;36(7):540-545. doi: 10.1080/1120009X.2024.2340877. Epub 2024 Apr 12.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is challenging to treat due to a lack of guidance for clinicians. The daptomycin and ceftaroline combination is promising for treating persistent MRSA bloodstream infections (BSIs). In this report, we present a case series of 7 patients who failed vancomycin and then were treated with daptomycin and ceftaroline for persistent MRSA BSIs. The median age (IQR) of the included patients was 59 (48-67), with 5 male and 2 female patients. Six patients (85.7%) had a clinical cure for their persistent BSIs. The median time (IQR) for sterilization of MRSA BSIs after initiation of daptomycin and ceftaroline combination was 2 days (1-3). Among the patients who had clinical cures, the median time for clinical cures (IQR) was 6 weeks (4.5-6 weeks). The combination of daptomycin and ceftaroline could be an excellent treatment option for persistent MRSA BSIs.

Keywords: Daptomycin; MRSA; antimicrobial resistance; bacteremia; bloodstream infections; ceftaroline.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents* / therapeutic use
  • Bacteremia* / drug therapy
  • Bacteremia* / microbiology
  • Ceftaroline*
  • Cephalosporins* / therapeutic use
  • Daptomycin* / therapeutic use
  • Drug Therapy, Combination*
  • Female
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus* / drug effects
  • Middle Aged
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Treatment Outcome

Substances

  • Ceftaroline
  • Daptomycin
  • Cephalosporins
  • Anti-Bacterial Agents